By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Teva Pharmaceutical Industries Ltd. et al. v. Amgen Inc.
2:09-cv-02256; filed May 20, 2009 in the Eastern District of Pennsylvania
Infringement of U.S. Patent No. 7,449,603 ("Process for the Preparation of Cinacalcet Base," issued November 11, 2008) based on Amgen's manufacture and sale of its Sensipar® (cinacalcet hydrochloride, used to treat secondary hyperparathyroidism in patients on dialysis, and hypercalcemia in patients with parathyroid carcinoma). View the complaint here.
Takeda Pharmaceutical Co. et al. v. Teva Pharmaceutical Industries, Ltd. et al.
1:09-cv-04665; filed May 18, 2009 in the Southern District of New York
Infringement of U.S. Patent Nos. 5,965,584 ("Pharmaceutical Composition," issued October 12, 1999), 6,329,404 (same title, issued December 11, 2001), 6,166,043 (same title, issued December 26, 2000), 6,172,090 (same title, issued January 9, 2001), 6,211,205 (same title, issued April 3, 2001), 6,271,243 (same title, issued August 7, 2001), and 6,303,640 (same title, issued October 16, 2001) following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Takeda's Actoplus MET® (pioglitazone hydrochloride and metformin, used to treat type II diabetes). View the complaint here.
CIMA Labs Inc. et al. v. Barr Laboratories Inc. et al.
1:09-cv-00349; filed May 15, 2009 in the District Court of Delaware
Infringement of U.S. Patent Nos. 6,024,981 ("Rapidly Dissolving Robust Damage Form," issued February 15, 2000) and 6,221,392 (same title, issued April 24, 2001), licensed to Azur Pharma, following a Paragraph IV certification as part of Barr's filing of an ANDA to manufacture a generic version of Azur's FazaClo® (clozapine, used to treat schizophrenia). View the compliant here.
TET Systems Holding GmBH & Co. KG v. Pharmasset, Inc.
3:09-cv-02230; filed May 11, 2009 in the District Court of New Jersey
Infringement of U.S. Patent No. 5,464,758 ("Tight Control of Gene Expression in Eucaryotic Cells by Tetracycline-Responsive Promoters," issued November 7, 1995) based on Pharmasset's development of pharmaceutical compositions through the use of the plaintiff's TET System. View the complaint here.
"As for Bilski, Ms. Dollard compared the case with KSR International Co. v. Teleflex Inc., "where we thought the world was going to end," and stated that the impact of Bilski could ultimately be less significant than first thought."
Who is "we"?
Posted by: Keep It Real | May 28, 2009 at 10:54 AM